由于乳腺癌的高发病率和全身治疗成本的增加，乳腺癌的财务影响已被讨论，并且在社会经济发展水平较低和中等的国家中更为重要。 评估使用 MammaPrint™ (MP) 基因特征的财务可行性在社会经济发展指数中等的国家的公共和私营系统中进行。一项药物经济学试验，进行成本效益分析，评估高危激素受体阳性患者化疗、支持药物和化疗输注期间使用的材料的成本降低情况(HR) 乳腺癌患者使用 MammaPrint™ 基因签名进行分析。在统一医疗系统 (SUS) 中使用 MammaPrint™ 的价值将为 50 岁以上年龄组中的每位患者带来 1,334.56 美元的额外费用。在私人医疗领域，在同一人群中使用 MammaPrint™ 将为每位患者节省 2,422.53 美元至 9,989.95 美元的成本。在巴西，MP 在具有高临床风险和低基因组风险的 RH 乳腺癌患者中的使用处于领先地位当应用于补充医疗保健时可以显着节省资源。在 SUS 中，降低大规模使用 MP 的成本可以使其应用可行。这些值需要在每个机构中使用试验中应用的方法重新评估，根据成本进行调整，以获得反映其现实的结果。版权所有 © 2024。由 Elsevier Ltd 出版。

The financial impact of breast cancer has been discussed due to its high incidence and the increased costs of systemic therapy and is even more relevant in countries with low and medium socioeconomic development.To evaluate the financial viability of using the MammaPrint™ (MP) genetic signature in a public and private system in a country with a medium socioeconomic development index.A pharmacoeconomic trial with a cost-benefit analysis evaluating the reduction in costs of chemotherapy, support drugs, and materials used during chemotherapy infusion in high-risk hormone receptor-positive (HR+) breast cancer patients submitted to analysis using the MammaPrint™ genetic signature.The value of using MammaPrint™ in the Unified Health System (SUS) would bring an additional cost of US$ 1,334.56 per patient in the over-50 age group. In private medicine, the use of MammaPrint™ in the same population would result in cost savings ranging from US$ 2,422.53 to US$ 9,989.95 per patient.The use of MP in RH + breast cancer patients with high clinical risk and low genomic risk in Brazil leads to significant savings in resources when applied to supplementary healthcare. In the SUS, reducing the costs of MP for large-scale use could make its application viable. These values need to be re-evaluated in each institution, using the methodology applied in the trial, adjusting according to costs, to obtain a result that reflects its reality.Copyright © 2024. Published by Elsevier Ltd.